All In Biotech

Investigational drug · Phase 3

Inhaled Treprostinil

Also called: LIQ861 Inhaled Treprostinil, Inhaled prostacyclin

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

3 still active

All registered trials

57

Any phase or sponsor naming "Inhaled Treprostinil"

First trial start

2019

Jul 18, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Inhaled Treprostinil", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Interstitial Lung Disease
  • Idiopathic Pulmonary Fibrosis
  • Progressive Pulmonary Fibrosis
  • Primary Pulmonary Hypertension

Approved drugs for the same conditions: High blood pressure (hypertension) · Idiopathic pulmonary fibrosis · Cardiovascular and metabolic · Respiratory

Largest trials

Live from ClinicalTrials.gov: studies naming "Inhaled Treprostinil" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 324 on PubMed

Also in development for Interstitial Lung Disease

  • MK-7240PRA023, TulisokibartPhase 310 trials

    Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease

  • INS1009Treprostinil PalmitilPhase 37 trials

    Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension

  • ATYR1923KRP-R120, EfzofitimodPhase 32 trials

    aTyr Pharma, Inc. · Interstitial Lung Disease, Pulmonary Sarcoidosis

  • MosliciguatPhase 32 trials

    Pulmovant, Inc. · Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.